Announcements Trials
Browse Landscape

Status

Recruiting 2Completed 2Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Surveys and Questionnaires 39Blood Specimen Collection 24Specimen Handling 14Radiotherapy 12Interviews as Topic 10Surgical Procedures, Operative 9Observation 9Magnetic Resonance Spectroscopy 9Drug Therapy 9Data Collection 8Immunotherapy 7Watchful Waiting 5Tomography, X-Ray Computed 5Radiosurgery 5Nivolumab 5Mental Status and Dementia Tests 5Mastectomy, Segmental 5Biopsy 5ribociclib 4palbociclib 4Therapeutics 4Positron Emission Tomography Computed Tomography 4Magnetic Resonance Imaging 4Ipilimumab 4Immune Checkpoint Inhibitors 4High-Throughput Nucleotide Sequencing 4Echocardiography 4Bevacizumab 4lorlatinib 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Observational × Combined Modality Therapy × Clear all
NCT07018427 2025-06-12

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Peking University Cancer Hospital & Institute

Active not recruiting
70 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡